Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Live Oak Private Wealth LLC

Live Oak Private Wealth LLC decreased its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,171 shares of the medical equipment provider's stock after selling 10,018 shares during the period. Live Oak Private Wealth LLC's holdings in Zimmer Biomet were worth $5,741,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. New World Advisors LLC acquired a new position in Zimmer Biomet during the 4th quarter worth about $366,000. Wealth Effects LLC acquired a new position in Zimmer Biomet during the 4th quarter worth about $205,000. Round Rock Advisors LLC acquired a new position in Zimmer Biomet during the 4th quarter worth about $231,000. Cerity Partners LLC increased its holdings in Zimmer Biomet by 40.8% during the 4th quarter. Cerity Partners LLC now owns 17,344 shares of the medical equipment provider's stock worth $2,112,000 after purchasing an additional 5,024 shares during the period. Finally, Impax Asset Management Group plc increased its holdings in Zimmer Biomet by 6.9% during the 4th quarter. Impax Asset Management Group plc now owns 4,601 shares of the medical equipment provider's stock worth $560,000 after purchasing an additional 297 shares during the period. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

ZBH traded down $3.04 during trading on Friday, hitting $124.48. 1,044,650 shares of the stock were exchanged, compared to its average volume of 1,487,626. The firm has a market capitalization of $25.58 billion, a P/E ratio of 25.46, a PEG ratio of 2.35 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $149.25. The stock has a fifty day moving average price of $126.73 and a two-hundred day moving average price of $118.83. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter in the previous year, the company posted $1.88 earnings per share. The firm's revenue was up 6.3% compared to the same quarter last year. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a dividend yield of 0.77%. Zimmer Biomet's dividend payout ratio (DPR) is currently 19.63%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.95% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. StockNews.com downgraded Zimmer Biomet from a "strong-buy" rating to a "buy" rating in a report on Monday, February 19th. TheStreet upgraded Zimmer Biomet from a "c" rating to a "b-" rating in a report on Thursday, February 8th. Citigroup upped their price target on Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a report on Wednesday, April 3rd. Canaccord Genuity Group restated a "hold" rating and set a $130.00 price target on shares of Zimmer Biomet in a report on Friday, February 23rd. Finally, Barclays upped their price target on Zimmer Biomet from $120.00 to $130.00 and gave the stock an "underweight" rating in a report on Monday, February 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.